New Research Concludes EU will Miss Climate Goals Unless Cleantech Innovation Is Scaled
23.3.2021 12:37:00 EET | Business Wire | Press release
Newly-published research from Cleantech Group®, the global authority on clean technology innovation, with the support of Breakthrough Energy, found the EU’s venture capital investment into cleantech from 2011-2020 grew by a remarkable 7.5x to more than EUR 5 billion in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005539/en/
EU Cleantech Venture Capital Investment grew by 7.5x between 2011 and 2020 (Cleantech Group)
But research also discovered progress is concentrated on early-stage development and lacks scale-up investment and policy support. The EU attracted 23% of global cleantech seed-stage funding in 2020, but only 7% of global cleantech growth equity funding (compared to 54% for North America). The EU risks missing key climate targets by failing to scale clean technologies and letting promising innovators scale in North America and Asia instead.
Cleantech for Europe is a new initiative launched by Cleantech Group®, with the support of Breakthrough Energy, to help the EU lead the global clean transformation through targeted research and recommendations on EU cleantech investment and policy. The initiative connects EU policy makers to entrepreneurs and investors.
Its first position paper, published today, Making Fit for 55 a green demand shock to scale EU cleantech, analyses the EU cleantech landscape. It advocates for leveraging the EU’s upcoming Fit for 55 regulatory package to create leadership in five key innovation sectors: green hydrogen, green steel, low-carbon construction materials, sustainable aviation and soil carbon. The paper makes the case for a green demand shock that would pull EU innovators to continental scale and maximize climate impact.
“The EU’s climate future is at a crossroads. Deploying mature technologies such as solar and wind can only take us halfway. To lead the race to net zero, and gain a competitive advantage for decades, the EU needs a green demand shock to scale early-stage clean technologies” said Jules Besnainou, Director, Cleantech Group.
“With the forthcoming ‘Fit for 55’ package, the EU will update almost all of its energy and climate legislation, changing the policy framework for a long time to come. With investment cycles averaging 25 years, what happens in 2050 is essentially being decided today. The stakes couldn’t be higher as only a new generation of clean technologies can lead Europe towards climate neutrality. That is why this study sheds light on persistent challenges in the European innovation ecosystem that urgently need to be addressed – from lack of growth equity and weak demand signals for green products to poor exit routes for successful entrepreneurs” said Ann Mettler, Vice President, Europe, Breakthrough Energy.
Link to research: https://www.cleantechforeurope.com/
About Cleantech Group
At Cleantech Group, we provide research, consulting and events to catalyze opportunities for sustainable growth powered by innovation. We bring clients access to the trends, companies and people shaping the future and the customized advice and support businesses need to engage external innovation. Industries are undergoing definitive transitions toward a more digitized, de-carbonized and resource-efficient industrial future. At every stage from initial strategy to final deals, our services bring corporate change makers, investors, governments and stakeholders from across the ecosystem, the support they need to thrive in this fast-arriving and uncertain future.
The company was established in 2002 and is headquartered in San Francisco with people based in London, Paris and Boston.
About Breakthrough Energy
Founded by Bill Gates, Breakthrough Energy is dedicated to helping humanity avoid a climate disaster. Through investment vehicles, philanthropic programs, policy advocacy, and other activities, we’re committed to scaling the technologies we need to reach net-zero emissions by 2050. For more information about Breakthrough Energy visit breakthroughenergy.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005539/en/
Contact information
Jules Besnainou
Director, Cleantech Group
hello@cleantechforeurope.com
+33 6 23 12 00 08
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
